Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Revenue: JPY43.7bn (+18.0% YoY), Operating profit: JPY10.6bn (+125.8% YoY), Recurring profit: JPY14.1bn (+135.7% YoY), Net Income: JPY11.2bn (+158.1% YoY).</li><li>Domestic business revenue: JPY40.1bn (+21.7% YoY), China business revenue: JPY3.6bn (-12.1% YoY), Prescription Kampo formulations revenue: JPY38.8bn (+21.9% YoY).</li><li>Cost of revenue ratio decreased by 7.2pp to 47.7%, SG&A expense ratio decreased by 4.3pp to 28.1%, driven by higher sales.</li></ul>

Revenue: JPY43.7bn (+18.0% YoY), Operating profit: JPY10.6bn (+125.8% YoY), Recurring profit: JPY14.1bn (+135.7% YoY), Net Income: JPY11.2bn (+158.1% YoY).Domestic business revenue: JPY40.1bn (+21.7% YoY), China business revenue: JPY3.6bn (-12.1% YoY), Prescription Kampo formulations revenue: JPY38.8bn (+21.9% YoY).Cost of revenue ratio decreased by 7.2pp to 47.7%, SG&A expense ratio decreased by 4.3pp to 28.1%, driven by higher sales.

Tsumura & Co (4540 JP): Q1 FY03/25 flash update